Welcome to our dedicated page for Genpact SEC filings (Ticker: G), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genpact Limited filings document the disclosures of a Bermuda-based operating company listed on the NYSE and focused on agentic and advanced technology solutions. Its 8-K reports furnish quarterly and annual results, include non-GAAP reconciliations, and describe operating categories such as Advanced Technology Solutions and Core Business Services.
Genpact's proxy and annual meeting filings cover board elections, executive compensation votes, auditor matters and shareholder voting results. Other filings document material agreements and capital structure, including senior unsecured notes issued by indirect wholly owned subsidiaries and guaranteed within the Genpact group, as well as officer appointments and related governance disclosures.
AQR Capital Management Holdings, LLC and AQR Capital Management, LLC reported beneficial ownership of 11,278,646 common shares of Genpact Ltd. That stake represents 6.64% of Genpact's outstanding common shares as of 03/31/2026. The filing shows shared voting power of 10,971,639 shares and shared dispositive power of 11,278,646 shares. The filing identifies AQR Capital Management, LLC as a wholly owned subsidiary of AQR Capital Management Holdings, LLC and is signed by an authorized signatory on behalf of both entities.
Genpact Limited reported higher results for the quarter ended March 31, 2026. Net revenues rose to $1,296,072 thousand from $1,214,926 thousand a year earlier, while net income increased to $147,992 thousand from $130,853 thousand. Diluted earnings per share improved to $0.86 from $0.73.
Operating cash flow turned negative at $(23,535) thousand versus positive $40,436 thousand in the prior-year quarter, reflecting higher working capital use. Cash and cash equivalents declined to $578,079 thousand from $853,836 thousand at year-end 2025, partly after paying a $77,500 thousand earn-out related to the XponentL Data acquisition. Total assets were $5,617,239 thousand and equity was $2,475,193 thousand as of March 31, 2026.
Genpact Limited reported solid first quarter 2026 results with net revenues of $1.296 billion, up 6.7% year-over-year. Advanced Technology Solutions revenue grew 24.3% to $345 million, reaching 27% of total net revenues, while Core Business Services rose 1.4% to $951 million.
Gross profit increased to $472 million with a margin of 36.4%, marking the 12th consecutive quarter of year-over-year gross margin expansion. Net income was $148 million, up 13.1%, and diluted EPS was $0.86, up 17.8%. Adjusted diluted EPS was $0.98, up 16.7%.
Operating cash flow was a use of $24 million compared to $40 million generated in the prior-year quarter, and the company repurchased about 1.8 million shares for roughly $70 million. For Q2 2026, Genpact guides net revenues of $1.324–$1.336 billion and adjusted diluted EPS of $0.96–$0.97. For full-year 2026, it expects net revenue growth of at least 7% and adjusted diluted EPS growth of more than 10%.
Genpact Limited reported solid first quarter 2026 results with net revenues of $1.296 billion, up 6.7% year-over-year. Advanced Technology Solutions revenue grew 24.3% to $345 million, reaching 27% of total net revenues, while Core Business Services rose 1.4% to $951 million.
Gross profit increased to $472 million with a margin of 36.4%, marking the 12th consecutive quarter of year-over-year gross margin expansion. Net income was $148 million, up 13.1%, and diluted EPS was $0.86, up 17.8%. Adjusted diluted EPS was $0.98, up 16.7%.
Operating cash flow was a use of $24 million compared to $40 million generated in the prior-year quarter, and the company repurchased about 1.8 million shares for roughly $70 million. For Q2 2026, Genpact guides net revenues of $1.324–$1.336 billion and adjusted diluted EPS of $0.96–$0.97. For full-year 2026, it expects net revenue growth of at least 7% and adjusted diluted EPS growth of more than 10%.
Genpact Ltd ownership filing reports that Vanguard Capital Management beneficially owned 8,674,784 shares of Genpact common stock, representing 5.10% of the class as of 03/31/2026. The filing discloses sole voting power for 1,216,854 shares and sole dispositive power for 8,674,784 shares. The filing notes these holdings reflect securities managed by Vanguard Capital Management and certain affiliated Vanguard business divisions.
Vanguard Portfolio Management reports beneficial ownership of 8,705,834 shares of Genpact Ltd Common Stock, representing 5.12% of the class. The filing shows Vanguard Portfolio Management has sole dispositive power over 8,705,834 shares and sole voting power for 62,760 shares as reported on 03/31/2026.
The disclosure states these holdings reflect securities managed by Vanguard Portfolio Management LLC and affiliated business divisions, including shares held for Vanguard funds and client accounts.
Genpact Limited held its 2026 annual general meeting on April 23, 2026, where shareholders voted on director elections, executive pay and the auditor appointment. All ten board nominees were elected, each receiving over 128 million votes in favor, with broker non-votes of 9,589,913 for each director.
Shareholders approved, on a non-binding advisory basis, compensation for named executive officers, with 125,882,016 votes in favor, 9,847,642 against and 165,272 abstentions, plus 9,589,913 broker non-votes. They also approved appointing KPMG Assurance and Consulting Services LLP as independent registered public accounting firm for fiscal 2026, with 134,484,965 votes in favor, 10,944,301 against and 55,577 abstentions.
Hinshaw John M reported acquisition or exercise transactions in this Form 4 filing.
Genpact LTD director John M. Hinshaw received an equity award in the form of restricted share units. He was granted 6,521 unvested RSUs, each entitling him to one common share in the future. Subject to his continued service, these RSUs will fully vest on December 31, 2026 and will be settled in common shares on December 31, 2027. Following this grant, he holds 8,855 common shares directly.
Morken CeCelia reported acquisition or exercise transactions in this Form 4 filing.
Genpact Ltd director CeCelia Morken received an equity grant in the form of restricted share units (RSUs). The award covers 6,521 common shares granted at no cash cost under the Genpact Limited 2017 Omnibus Incentive Compensation Plan. Each RSU entitles her to one common share at a future date, subject to continued service. The RSUs will fully vest on December 31, 2026 and will be settled in common shares on December 31, 2027. Following this grant, she directly holds 64,281 common shares.
Genpact LTD director Carol Lindstrom received an equity award of 6,521 common-share RSUs. The grant, priced at $0.00 per unit as compensation, increases her direct holdings to 27,706 common shares after the award. Each restricted share unit entitles her to one common share at a future date.
According to the award terms, all RSUs will fully vest on December 31, 2026, assuming she continues in service, and will be settled in common shares on December 31, 2027. This is a non-market, compensation-related acquisition rather than an open-market purchase.
Gangestad Nicholas C reported acquisition or exercise transactions in this Form 4 filing.
Genpact LTD director Nicholas C. Gangestad received an equity grant in the form of restricted share units. He was awarded 6,521 unvested RSUs, each representing one common share at a future date, increasing his direct holdings to 15,334 common shares after the award.
The RSUs were granted under the Genpact Limited 2017 Omnibus Incentive Compensation Plan. Subject to his continued service, the entire RSU award will vest on December 31, 2026 and will be settled in common shares on December 31, 2027, aligning his compensation further with long-term shareholder interests.